ABIOMED, Inc. (ABMD)
ABMD Price and Sentiment
ABMD Latest news
Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes2021-11-04 08:05
ORLANDO, Fla.--(BUSINESS WIRE)--Two large studies demonstrate complete revascularization with Impella heart pumps improves ejection fraction and long-term patient outcomes.
DANVERS, Mass.--(BUSINESS WIRE)--The 2021 ESC guidelines for treatment of acute heart failure patients elevate technology such as Impella to Class IIa ("should be considered").
TCT 2021 to Highlight Improved Patient Outcomes with Impella's Small, Smart and Connected Technology2021-11-01 07:58
DANVERS, Mass.--(BUSINESS WIRE)--TCT 2021 showcases data and clinical studies supporting the use of Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure.
Abiomed's (ABMD) CEO Mike Minogue on Q2 2022 Results - Earnings Call Transcript
Abiomed (ABMD) delivered earnings and revenue surprises of 5.10% and -0.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q2 fiscal year 2022 revenue of $248 million, up 18% year over year.
Abiomed (NASDAQ:ABMD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.